[go: up one dir, main page]

WO2008031835A3 - Method of treating autoimmune diseases using vegf-pathway inhibitors - Google Patents

Method of treating autoimmune diseases using vegf-pathway inhibitors Download PDF

Info

Publication number
WO2008031835A3
WO2008031835A3 PCT/EP2007/059559 EP2007059559W WO2008031835A3 WO 2008031835 A3 WO2008031835 A3 WO 2008031835A3 EP 2007059559 W EP2007059559 W EP 2007059559W WO 2008031835 A3 WO2008031835 A3 WO 2008031835A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
autoimmune disease
autoimmune diseases
pathway inhibitors
treating autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/059559
Other languages
French (fr)
Other versions
WO2008031835A2 (en
Inventor
Peter C Hiestand
Christian Schnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of WO2008031835A2 publication Critical patent/WO2008031835A2/en
Publication of WO2008031835A3 publication Critical patent/WO2008031835A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a method of treating a warm-blooded animal having an autoimmune disease, such as multiple sclerosis, peripheral neuritis, optical neuritis, amyotrophic lateral sclerosis or uveitis, comprising administering to said animal a therapeutically effective amount of a VEGF-pathway inhibitor, e.g. Bevacizumab, Sunitinib or Sorafenib, alone or in combination with further therapeutic measures; the use of a VEGF-pathway inhibitor for the preparation of a medicament for the treatment of an autoimmune disease; and to a commercial package comprising such a medicament together with instructions for its use in the treatment of an autoimmune disease.
PCT/EP2007/059559 2006-09-13 2007-09-12 Method of treating autoimmune diseases using vegf-pathway inhibitors Ceased WO2008031835A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120606.6 2006-09-13
EP06120606 2006-09-13

Publications (2)

Publication Number Publication Date
WO2008031835A2 WO2008031835A2 (en) 2008-03-20
WO2008031835A3 true WO2008031835A3 (en) 2008-05-22

Family

ID=37726915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/059559 Ceased WO2008031835A2 (en) 2006-09-13 2007-09-12 Method of treating autoimmune diseases using vegf-pathway inhibitors

Country Status (1)

Country Link
WO (1) WO2008031835A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102076844B (en) 2008-06-30 2013-08-07 成血管细胞系统公司 Treatment of eye diseases and excessive neovascularization using a combined therapy
FR2945210B1 (en) * 2009-05-07 2011-07-01 Sanofi Aventis ANTITUMOR COMBINATION COMPRISING AVE8062 AND SORAFENIB
US20110112121A1 (en) * 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
JP5835729B2 (en) * 2010-09-02 2015-12-24 国立大学法人京都大学 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
RU2523146C1 (en) * 2013-04-08 2014-07-20 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Method of treating monocular optic neuritis accompanying multiple sclerosis
CN107530430A (en) * 2015-01-13 2018-01-02 国立大学法人京都大学 Medicaments for preventing and/or treating amyotrophic lateral sclerosis
AU2017217677A1 (en) 2016-02-08 2018-07-26 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
WO2005009367A2 (en) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
WO2006020145A2 (en) * 2004-07-19 2006-02-23 The Johns Hopkins University Flt3 inhibitors for immune suppression
WO2006059234A2 (en) * 2004-09-15 2006-06-08 Novartis Ag Bicyclic amides as kinase inhibitors
US20060134111A1 (en) * 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
WO2005009367A2 (en) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
WO2006020145A2 (en) * 2004-07-19 2006-02-23 The Johns Hopkins University Flt3 inhibitors for immune suppression
WO2006059234A2 (en) * 2004-09-15 2006-06-08 Novartis Ag Bicyclic amides as kinase inhibitors
US20060134111A1 (en) * 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FISHER WILSON J: "Angiogenesis therapy moves beyond cancer", ANNALS OF INTERNAL MEDICINE, NEW YORK, NY, US, vol. 141, no. 2, 20 July 2004 (2004-07-20), pages 165 - 168, XP002378544, ISSN: 0003-4819 *
MANLEY P W ET AL: "Therapies directed at vascular endothelial growth factor", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 11, no. 12, December 2002 (2002-12-01), pages 1715 - 1736, XP002256125, ISSN: 1354-3784 *

Also Published As

Publication number Publication date
WO2008031835A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2008076847A3 (en) Regional delivery of therapeutic agents for the treatment of vascular diseases
BR112014008789A2 (en) prevention and treatment of eye conditions
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
UA103614C2 (en) Medicinal composition for treating hepatic cancer which comprises a kinase inhibitor. combined with glypican 3 antibody
WO2008031835A3 (en) Method of treating autoimmune diseases using vegf-pathway inhibitors
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
EA201490378A1 (en) TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β
MY168763A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
MX2009011900A (en) Diabetic wound healing.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MX2012001708A (en) Humanized anti-amyloid-î oligomer antibody.
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07803423

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07803423

Country of ref document: EP

Kind code of ref document: A2